Rapid and dramatic responses have been observed with oncogene-directed treatments, such as BRAF inhibitors in melanoma and epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.